Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.64 |
| ▸ | HTR2A | P28223 | 5/20 | 0.47 |
| ▸ | DRD2 | P14416 | 5/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | HTR1D | P28221 | 1/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 3/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.46 |
| ▸ | HTR7 | P34969 | 4/20 | 0.43 |
| ▸ | HTR6 | P50406 | 4/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139454 | 0.92 | HTR1A (0.64) | HTR1ASLC6A4HTR2ADRD2NOS3 | |
| SCHEMBL4153116 | 0.91 | HTR1A (0.68) | HTR1ASLC6A4HTR2ADRD2NOS3 | |
| SCHEMBL4139201 | 0.90 | HTR1A (0.80) | HTR1ASLC6A4HTR2ADRD2NOS3 | |
| SCHEMBL4140755 | 0.89 | HTR1A (0.65) | HTR1ASLC6A4HTR2ADRD2NOS3 | |
| SCHEMBL4134004 | 0.86 | HTR1A (0.61) | HTR1ASLC6A4HTR2ADRD2NOS3 | |
| SCHEMBL4144003 | 0.84 | HTR1A (0.68) | HTR1ASLC6A4HTR2ADRD2NOS3 | |
| SCHEMBL4139895 | 0.83 | HTR1A (0.81) | HTR1ASLC6A4HTR2ADRD2NOS3 | |
| SCHEMBL4139440 | 0.83 | HTR1A (0.72) | HTR1ASLC6A4HTR2ADRD2NOS3 | |
| SCHEMBL4139852 | 0.81 | HTR1A (0.65) | HTR1ASLC6A4HTR2ADRD2NOS3 | |
| SCHEMBL4131026 | 0.81 | HTR1A (0.62) | HTR1ASLC6A4DRD2KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | claimed |
| EP-1641785-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS | Wyeth (US) | 2006-04-05 | — | — | EP | claimed |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | WYETH | 2005-03-17 | — | — | US | claimed |
| WO-2004099191-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS | WYETH (US) | 2004-11-18 | — | — | WO | claimed |
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | VENKATESAN ARANAPAKAM MUDUMBAI | 2009-02-26 | — | — | US | disclosed |
| US-7276603-B2 | serotonin receptor antagonists such as 8-{4-[2-(1-benzofuran-3-yl)ethyl]-1-piperazinyl}-6-fluoroquinoline, used for treatment and/or prevention of depression, anxiety and cognitive deficits arising from Alzheimer's disease, neurodegenerative disorders, schizophrenia and prostate cancer | WYETH (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1641785-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIBITORS | Wyeth (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | WYETH | 2005-03-17 | — | — | US | disclosed |
| WO-2004099191-A2 | BENZOFURANYL-AND BENZOTHIENYL-PIPERAZINYL QUINOLINES AS SEROTONIN REUPTAKE INHIB ITORS | WYETH (US) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054454-A1 | BENZOFURANYL- AND BENZOTHIENYL- PIPERAZINYL QUINOLINES AND METHODS OF THEIR USE | TPH1, TPH2, HTR2C | HTR1A 12/4885SLC6A4 14/4885HTR2A 7/4885 |
| US-20050059673-A1 | Benzofuranyl-and benzothienyl-piperazinyl quinolines and methods of their use | TPH1, TPH2, HTR2C | HTR1A 12/4885SLC6A4 14/4885HTR2A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.